Lacosamide controlled release - Adamas Pharmaceuticals

Drug Profile

Lacosamide controlled release - Adamas Pharmaceuticals

Alternative Names: ADS 4101; Lacosamide extended release capsule

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 21 Apr 2018 Pooled pharmacokinetic and adverse events data from two phase I trials in Epilepsy presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
  • 15 Mar 2018 Adamas Pharmaceuticals plans a pivotal phase III trial for Epilepsy in USA (PO) in 2019
  • 15 Mar 2018 Adamas Pharmaceuticals plans a phase III open-label extension trial for Epilepsy in USA (PO) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top